SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques
Autor: | Nuria Guimera, Liesbeth Dekking, Sarah Tete, Dominika N. Czapska-Casey, Juan J. Perez-Ruixo, Joan E.M. van der Lubbe, Jan Serroyen, Jenny Hendriks, Roel Straetemans, Daniel J. Stieh, Wouter Koudstaal, Hanneke Schuitemaker, Dan H. Barouch, Roland Zahn, Frank Wegmann, Jingyou Yu, Sietske K. Rosendahl Huber, Mathieu Le Gars, Anna Dari, Jerry Sadoff, Abishek Chandrashekar, Laura Solforosi, Noe B. Mercado, Ramon Roozendaal, Sarah Janssen, Muriel Boulton |
---|---|
Rok vydání: | 2021 |
Předmět: |
Male
COVID-19 Vaccines Science General Physics and Astronomy Nose Antibodies Viral Virus Replication Predictive markers General Biochemistry Genetics and Molecular Biology Article Immunity Medicine Animals Humans Neutralizing antibody Lung Vaccines Multidisciplinary biology Ad26COVS1 business.industry SARS-CoV-2 Immunogenicity Vaccination Antibody titer COVID-19 General Chemistry Virology Antibodies Neutralizing Macaca mulatta Immunity Humoral HEK293 Cells Logistic Models Immunization Viral replication Viral infection Spike Glycoprotein Coronavirus biology.protein Female Antibody business |
Zdroj: | Nature Communications Nature Communications, Vol 12, Iss 1, Pp 1-10 (2021) |
ISSN: | 2041-1723 |
Popis: | Several COVID-19 vaccines have recently gained authorization for emergency use. Limited knowledge on duration of immunity and efficacy of these vaccines is currently available. Data on other coronaviruses after natural infection suggest that immunity to SARS-CoV-2 might be short-lived, and preliminary evidence indicates waning antibody titers following SARS-CoV-2 infection. In this work, we model the relationship between immunogenicity and protective efficacy of a series of Ad26 vectors encoding stabilized variants of the SARS-CoV-2 Spike protein in rhesus macaques and validate the analyses by challenging macaques 6 months after immunization with the Ad26.COV2.S vaccine candidate that has been selected for clinical development. We show that Ad26.COV2.S confers durable protection against replication of SARS-CoV-2 in the lungs that is predicted by the levels of Spike-binding and neutralizing antibodies, indicating that Ad26.COV2.S could confer durable protection in humans and immunological correlates of protection may enable the prediction of durability of protection. Several COVID-19 vaccines have received emergency approval, but durability of protection is unclear. Here, the authors describe correlates of protection (CoP) for the Ad26.COV2.S vaccine in rhesus macaques and report that CoP predict the protection observed 6 months post vaccination. |
Databáze: | OpenAIRE |
Externí odkaz: |